Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim for prevention of neutropenia during concurrent chemoradiotherapy
ChiCTR2200058551Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mecapegfilgrastim in bronchial carcinoma, esophageal cancer and Cervical Cancer (CC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Incidence of grade 3/4 neutropenia during concurrent chemoradiotherapy. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
bronchial carcinomaesophageal cancerCervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200058551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058551.